Compare EL & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EL | TEVA |
|---|---|---|
| Founded | 1946 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 30.2B |
| IPO Year | 1995 | N/A |
| Metric | EL | TEVA |
|---|---|---|
| Price | $105.05 | $29.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 9 |
| Target Price | ★ $95.05 | $29.78 |
| AVG Volume (30 Days) | 3.4M | ★ 10.9M |
| Earning Date | 10-30-2025 | 01-28-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | $14,446,000,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $7.34 | $4.74 |
| Revenue Next Year | $4.07 | $0.48 |
| P/E Ratio | ★ N/A | $45.91 |
| Revenue Growth | N/A | ★ 0.02 |
| 52 Week Low | $48.37 | $12.47 |
| 52 Week High | $105.78 | $29.10 |
| Indicator | EL | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.23 | 82.00 |
| Support Level | $102.15 | $28.00 |
| Resistance Level | $105.78 | $26.96 |
| Average True Range (ATR) | 2.86 | 0.63 |
| MACD | 1.39 | 0.14 |
| Stochastic Oscillator | 97.17 | 94.19 |
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%), with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.